Found: 63
Select item for more details and to access through your institution.
Prospective phase 2 trial of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment or on dialysis: The DARE study.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 9, p. E226, doi. 10.1002/ajh.27001
- By:
- Publication type:
- Article
Improved survival of patients with primary plasma cell leukemia with VRd or daratumumab‐based quadruplets: A multicenter study by the Greek myeloma study group.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 5, p. 730, doi. 10.1002/ajh.26891
- By:
- Publication type:
- Article
Real‐world data on incidence, clinical characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) in the era of novel therapies: A study of the Greco‐Israeli collaborative myeloma working group.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 5, p. 465, doi. 10.1002/ajh.25755
- By:
- Publication type:
- Article
Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: A report of the Greek myeloma study group in 97 patients.
- Published in:
- American Journal of Hematology, 2014, v. 89, n. 8, p. 803, doi. 10.1002/ajh.23745
- By:
- Publication type:
- Article
Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group.
- Published in:
- American Journal of Hematology, 2014, v. 89, n. 2, p. 145, doi. 10.1002/ajh.23600
- By:
- Publication type:
- Article
The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: Final results on 205 patients of the Greek myeloma study group.
- Published in:
- American Journal of Hematology, 2014, v. 89, n. 1, p. 34, doi. 10.1002/ajh.23577
- By:
- Publication type:
- Article
No significant improvement in the outcome of patients with Waldenström's macroglobulinemia treated over the last 25 years.
- Published in:
- American Journal of Hematology, 2011, v. 86, n. 6, p. 479, doi. 10.1002/ajh.22027
- By:
- Publication type:
- Article
New Insights into Malignant B-Cell Disorders.
- Published in:
- BioMed Research International, 2015, v. 2015, p. 1, doi. 10.1155/2015/128084
- By:
- Publication type:
- Article
Serum Soluble TACI, a BLyS Receptor, Is a Powerful Prognostic Marker of Outcome in Chronic Lymphocytic Leukemia.
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
Clonotypic Analysis of Immunoglobulin Heavy Chain Sequences in Patients with Waldenström's Macroglobulinemia: Correlation with MYD88 L265P Somatic Mutation Status, Clinical Features, and Outcome.
- Published in:
- BioMed Research International, 2014, v. 2014, p. 1, doi. 10.1155/2014/809103
- By:
- Publication type:
- Article
New Insights into Monoclonal B-Cell Lymphocytosis.
- Published in:
- BioMed Research International, 2014, v. 2014, p. 1, doi. 10.1155/2014/258917
- By:
- Publication type:
- Article
Immunohistochemical Analysis of IL-6, IL-8/CXCR2 Axis, <sup>Tyr</sup>p-STAT-3, and SOCS-3 in Lymph Nodes from Patients with Chronic Lymphocytic Leukemia: Correlation between Microvascular Characteristics and Prognostic Significance.
- Published in:
- BioMed Research International, 2014, v. 2014, p. 1, doi. 10.1155/2014/251479
- By:
- Publication type:
- Article
Serum Soluble TACI, a BLyS Receptor, Is a Powerful Prognostic Marker of Outcome in Chronic Lymphocytic Leukemia.
- Published in:
- BioMed Research International, 2014, v. 2014, p. 1, doi. 10.1155/2014/159632
- By:
- Publication type:
- Article
Study of bone metabolism and angiogenesis in patients undergoing high‐dose chemotherapy/autologous hematopoietic stem cell transplantation.
- Published in:
- European Journal of Haematology, 2018, v. 100, n. 2, p. 131, doi. 10.1111/ejh.12990
- By:
- Publication type:
- Article
Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies.
- Published in:
- European Journal of Haematology, 2017, v. 99, n. 5, p. 409, doi. 10.1111/ejh.12923
- By:
- Publication type:
- Article
Prognostic Value of Serum β2-Microglobulin in Patients with Waldenström's Macroglobulinemia Requiring Treatment.
- Published in:
- Clinical Lymphoma & Myeloma, 2006, v. 7, n. 3, p. 205
- By:
- Publication type:
- Article
The Role of Methylation in Chronic Lymphocytic Leukemia and Its Prognostic and Therapeutic Impacts in the Disease: A Systematic Review.
- Published in:
- Advances in Hematology, 2024, v. 2024, p. 1, doi. 10.1155/2024/1370364
- By:
- Publication type:
- Article
Prognostic Significance of Serum Free Light Chains in Chronic Lymphocytic Leukemia.
- Published in:
- Advances in Hematology, 2013, p. 1, doi. 10.1155/2013/359071
- By:
- Publication type:
- Article
Serum-Soluble CD163 Levels as a Prognostic Biomarker in Patients with Diffuse Large B-Cell Lymphoma Treated with Chemoimmunotherapy.
- Published in:
- International Journal of Molecular Sciences, 2024, v. 25, n. 5, p. 2862, doi. 10.3390/ijms25052862
- By:
- Publication type:
- Article
P-085: Updated outcomes on Lenalidomide (Len) refractory MM patients'.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S85, doi. 10.1016/S2152-2650(21)02219-9
- By:
- Publication type:
- Article
Real-world Data on Incidence, Clinical Characteristics and Outcome of Patients with Macrofocal Multiple Myeloma in the Novel Therapeutic Era: A study of the Greco-Israeli Collaborative Myeloma Working Group.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e190, doi. 10.1016/j.clml.2019.09.318
- By:
- Publication type:
- Article
A Revised Staging System for Waldenström's Macroglobulinemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S332, doi. 10.1016/j.clml.2017.07.146
- By:
- Publication type:
- Article
Real-World data for the Treatment of Relapsed/Refractory Multiple Myeloma with Lenalidomide and Dexamethasone in 2nd Line (Legend Study): The Prognostic Significance of Biochemical Versus Clinical Relapse.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e130, doi. 10.1016/j.clml.2017.03.236
- By:
- Publication type:
- Article
Validation of Frailty Assessment in Multiple Myeloma (MM) Patients.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e137, doi. 10.1016/j.clml.2017.03.247
- By:
- Publication type:
- Article
Phase 2 Study of the All-Oral Combination of Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e131, doi. 10.1016/j.clml.2017.03.237
- By:
- Publication type:
- Article
Circulating miR-16 and miR-21 Levels in Multiple Myeloma: Prognostic Significance of Survival and Response to Lenalidomide Treatment.
- Published in:
- International Journal of Molecular Sciences, 2024, v. 25, n. 11, p. 6065, doi. 10.3390/ijms25116065
- By:
- Publication type:
- Article
Bone metabolism markers and angiogenic cytokines as regulators of human hematopoietic stem cell mobilization.
- Published in:
- 2018
- By:
- Publication type:
- journal article
High levels of serum angiogenic growth factors in patients with AL amyloidosis: comparisons with normal individuals and multiple myeloma patients.
- Published in:
- British Journal of Haematology, 2010, v. 150, n. 5, p. 587, doi. 10.1111/j.1365-2141.2010.08288.x
- By:
- Publication type:
- Article
Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma.
- Published in:
- British Journal of Haematology, 2007, v. 137, n. 3, p. 240, doi. 10.1111/j.1365-2141.2007.06561.x
- By:
- Publication type:
- Article
Treatment of Splenic Marginal Zone Lymphoma With Rituximab Monotherapy: Progress Report and Comparison With Splenectomy.
- Published in:
- Oncologist, 2013, v. 18, n. 2, p. 190, doi. 10.1634/theoncologist.2012-0251
- By:
- Publication type:
- Article
Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone with or Without Radiotherapy in Primary Mediastinal Large B-Cell Lymphoma: The Emerging Standard of Care.
- Published in:
- Oncologist, 2012, v. 17, n. 2, p. 239, doi. 10.1634/theoncologist.2011-0275
- By:
- Publication type:
- Article
Early-Stage Gastric MALT Lymphoma: Is It a Truly Localized Disease?
- Published in:
- Oncologist, 2009, v. 14, n. 2, p. 148, doi. 10.1634/theoncologist.2008-0178
- By:
- Publication type:
- Article
Complete eradication of chronic lymphocytic leukemia with unusual skin involvement of high mitotic index after time‐limited venetoclax/obinutuzumab treatment.
- Published in:
- Clinical Case Reports, 2021, v. 9, n. 7, p. 1, doi. 10.1002/ccr3.4514
- By:
- Publication type:
- Article
Richter's transformation as leptomeningeal infiltration in a chronic lymphocytic leukemia patient receiving venetoclax. Could blood‐brain barrier be a disease "sanctuary" during venetoclax treatment?
- Published in:
- Clinical Case Reports, 2021, v. 9, n. 4, p. 2249, doi. 10.1002/ccr3.4002
- By:
- Publication type:
- Article
The prognostic significance of chromosome 17 abnormalities in patients with myelodysplastic syndrome treated with 5‐azacytidine: Results from the Hellenic 5‐azacytidine registry.
- Published in:
- Cancer Medicine, 2019, v. 8, n. 5, p. 2056, doi. 10.1002/cam4.2090
- By:
- Publication type:
- Article
Prognostic significance of signal transducer and activator of transcription 5 and 5b expression in Epstein-Barr virus-positive patients with chronic lymphocytic leukemia.
- Published in:
- Cancer Medicine, 2016, v. 5, n. 9, p. 2240, doi. 10.1002/cam4.804
- By:
- Publication type:
- Article
Has the time come to reevaluate prognostic factors and to rebuild staging systems for Multiple Myeloma?
- Published in:
- 2015
- By:
- Publication type:
- Editorial
Multiple myeloma in octogenarians: Clinical features and outcome in the novel agent era.
- Published in:
- European Journal of Haematology, 2012, v. 89, n. 1, p. 10, doi. 10.1111/j.1600-0609.2012.01784.x
- By:
- Publication type:
- Article
Hodgkin's lymphoma in first relapse following chemotherapy or combined modality therapy: analysis of outcome and prognostic factors after conventional salvage therapy.
- Published in:
- European Journal of Haematology, 2002, v. 68, n. 5, p. 289, doi. 10.1034/j.1600-0609.2002.01721.x
- By:
- Publication type:
- Article
Validation of the simplified International Prognostic Score3 in a Hellenic cohort of patients with advanced‐stage Hodgkin‐lymphoma.
- Published in:
- British Journal of Haematology, 2020, v. 190, n. 6, p. e335, doi. 10.1111/bjh.16903
- By:
- Publication type:
- Article
Phase 2 study of all‐oral ixazomib, cyclophosphamide and low‐dose dexamethasone for relapsed/refractory multiple myeloma.
- Published in:
- British Journal of Haematology, 2019, v. 184, n. 4, p. 536, doi. 10.1111/bjh.15679
- By:
- Publication type:
- Article
Cadherin-11 ( CDH11) expression in the peripheral blood of patients with active Multiple Myeloma.
- Published in:
- British Journal of Haematology, 2017, v. 177, n. 5, p. 813, doi. 10.1111/bjh.14105
- By:
- Publication type:
- Article
Novel M-component based biomarkers in Waldenström's macroglobulinemia.
- Published in:
- 2011
- By:
- Publication type:
- Journal Article
Prognostication of the high-risk WM patient.
- Published in:
- 2011
- By:
- Publication type:
- Journal Article
CD138 expression helps distinguishing Waldenström's macroglobulinemia (WM) from splenic marginal zone lymphoma (SMZL)
- Published in:
- 2011
- By:
- Publication type:
- Journal Article
Prognostication of the High-Risk WM Patient.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2011, v. 11, n. 1, p. 127, doi. 10.3816/CLML.2011.n.028
- By:
- Publication type:
- Article
Novel M-Component Based Biomarkers in Waldenström's Macroglobulinemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2011, v. 11, n. 1, p. 164, doi. 10.3816/CLML.2011.n.039
- By:
- Publication type:
- Article
CD138 Expression Helps Distinguishing Waldenström's Macroglobulinemia (WM) From Splenic Marginal Zone Lymphoma (SMZL).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2011, v. 11, n. 1, p. 99, doi. 10.3816/CLML.2011.n.019
- By:
- Publication type:
- Article
Clinical Characteristics and Outcome of Primary Systemic Light-Chain Amyloidosis in Greece.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2010, v. 10, n. 1, p. 56, doi. 10.3816/CLML.2010.n.006
- By:
- Publication type:
- Article
Serum Procalcitonin Levels in Newly Diagnosed Hodgkin Lymphoma: Correlation with Other Inflammatory Biomarkers.
- Published in:
- Medicina (1010660X), 2022, v. 58, n. 10, p. 1331, doi. 10.3390/medicina58101331
- By:
- Publication type:
- Article